B4GALNT2 (Gene)

Organism:

Homo sapiens

Synonyms:B4GALNT2, B4GALT, ENTREZ:124872, GALGT2, HGNC:24136, MIM:111730, NM_001159387, NM_001159388, NM_153446, NP_001152859, NP_001152860, NP_703147, XM_011524314, XM_017024173, XP_011522616, XP_016879662, beta-1,4-N-acetyl-galactosaminyltransferase 2

Omim:OMIM:111730

Id:ENSG00000167080

Hgnc:HGNC:24136

Entrez:124872

Ensembl:ENSG00000167080

Description:beta-1,4-N-acetyl-galactosaminyltransferase 2 (SID blood group)

B4GALNT2 catalyzes the last step in the biosynthesis of the human Sd(a) antigen through the addition of an N-acetylgalactosamine residue via a beta-1,4 linkage to a subterminal galactose residue substituted with an alpha-2,3-linked sialic acid. B4GALNT2 also catalyzes the last step in the biosynthesis of the Cad antigen (Montiel et al., 2003 [PubMed 12678917]).[supplied by OMIM, Mar 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View B4GALNT2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with B4GALNT2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using B4GALNT2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for B4GALNT2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with B4GALNT2.

Results found

Linked to

	Label	Description
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 7 V 5 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158456 2 V 3 FURIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE192860 0 V 1 TRIFLUOPERAZINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE230329 0 V 3 DEXTRAN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE165548 2 V 13 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE196117 6 V 8 CLARITHROMYCIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE145650 COX2 inhibition 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE120612 7 V 5 ETOPOSIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE158456 2 V 3 FURIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE192860 0 V 1 TRIFLUOPERAZINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE230329 0 V 3 DEXTRAN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE165548 2 V 13 GEMCITABINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE196117 6 V 8 CLARITHROMYCIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE145650 COX2 inhibition 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.